1
|
Sarma A, Gadde JA. Post-treatment Evaluation of Pediatric Head and Neck. Semin Roentgenol 2023; 58:363-373. [PMID: 37507176 DOI: 10.1053/j.ro.2023.03.005] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/12/2022] [Revised: 03/03/2023] [Accepted: 03/22/2023] [Indexed: 07/30/2023]
Affiliation(s)
- Asha Sarma
- Vanderbilt University Medical Center, Monroe Carell Jr Children's Hospital, Nashville, TN
| | - Judith A Gadde
- Ann and Robert H. Lurie Children's Hospital of Chicago, Chicago, IL.
| |
Collapse
|
2
|
Endara SA, Dávalos GA, Molina GA, Armijos CA, Narvaez DS, Montalvo N. Case Report: Desmoid fibromatosis in the mediastinum of a 6-month-old toddler, what to do? Front Surg 2023; 9:1007760. [PMID: 36793513 PMCID: PMC9923160 DOI: 10.3389/fsurg.2022.1007760] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/30/2022] [Accepted: 12/30/2022] [Indexed: 01/31/2023] Open
Abstract
Desmoid fibromatosis is a rare, aggressive borderline lesion arising from soft tissues. Treatment will depend on the structures that the tumor has involved. Surgery with negative margins is the recommended strategy as it can usually achieve disease control; however, the tumor's location sometimes does not allow it. Therefore, a combination of medical therapies along with strict surveillance is crucial. We present the case of a 6-month-old boy with a chest mass. After further evaluation, a rapidly growing mediastinal mass involving the sternum and costal cartilage was detected. Desmoid fibromatosis was the final diagnosis.
Collapse
Affiliation(s)
- Santiago A. Endara
- Department of General Surgery, Division of Cardiothoracic Surgery, Hospital Metropolitano, Quito-Ecuador,Correspondence: Santiago A. Endara
| | - Gerardo A. Dávalos
- Department of General Surgery, Division of Cardiothoracic Surgery, Hospital Metropolitano, Quito-Ecuador
| | | | - Christian A. Armijos
- Department of Internal Medicine, Imaging and Interventional Radiology Service, Hospital Metropolitano, Quito-Ecuador
| | - D. Sebastian Narvaez
- Universidad Internacional del Ecuador-Hospital Metropolitano PGY1 General Surgery, Quito-Ecuador
| | - Nelson Montalvo
- Department of Internal Medicine, Pathology Service, Hospital Metropolitano, Quito-Ecuador
| |
Collapse
|
3
|
Zhong YW, Lyu XM, Shi Y, Guo CB, Zhang JG, Zheng L. Long-term result of 125 I seed brachytherapy for pediatric desmoid tumor in the head and neck. Pediatr Blood Cancer 2023; 70:e30037. [PMID: 36184787 DOI: 10.1002/pbc.30037] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 07/13/2022] [Revised: 08/12/2022] [Accepted: 09/09/2022] [Indexed: 12/25/2022]
Abstract
BACKGROUND Desmoid tumor (DT) is rare and challenging, often affects the head and neck (HN) region in children, and its appropriate treatments are under-discussed. This study aimed to retrospectively evaluate the long-term effectiveness and safety of 125 I seed brachytherapy for pediatric DT in HN. PROCEDURE Seven pediatric patients with a median age of three years who suffered from DT in HN treated with 125 I brachytherapy from January 2008 to June 2018 were included. Among these, five underwent sole brachytherapy and the others combined with surgery under prescription doses ranging from 10,000 to 12,000 cGy. The rate of local control (LC), complete response (CR), and partial response (PR) was calculated after evaluation by radiological and pathological means. Radiation-associated toxicities were also evaluated. RESULTS The LC rate was 7/7 during the follow-up time ranging from 43 to 135 months and with a mean of 57 months. No recurrent lesion was found in the patients receiving surgery combined with brachytherapy. In patients treated with sole brachytherapy, the radiological PR rate and CR rate were 4/5 and 1/5, respectively. In those reaching radiological PR, 3/4 were pathological CR. Slight acute radiation-associated toxicities were observed in all patients, and no late or severe acute toxicity was observed. CONCLUSION 125 I brachytherapy is effective and safe in the management of pediatric DT in HN as the sole modality or combined with surgery in the long term.
Collapse
Affiliation(s)
- Yi-Wei Zhong
- Department of Oral and Maxillofacial Surgery, Peking University School and Hospital of Stomatology, Beijing, China.,National Center of Stomatology and National Clinical Research Center for Oral Diseases and National Engineering Laboratory for Digital and Material Technology of Stomatology, Beijing, China
| | - Xiao-Ming Lyu
- Department of Oral and Maxillofacial Surgery, Peking University School and Hospital of Stomatology, Beijing, China.,National Center of Stomatology and National Clinical Research Center for Oral Diseases and National Engineering Laboratory for Digital and Material Technology of Stomatology, Beijing, China
| | - Yan Shi
- Department of Oral and Maxillofacial Surgery, Peking University School and Hospital of Stomatology, Beijing, China.,National Center of Stomatology and National Clinical Research Center for Oral Diseases and National Engineering Laboratory for Digital and Material Technology of Stomatology, Beijing, China
| | - Chuan-Bin Guo
- Department of Oral and Maxillofacial Surgery, Peking University School and Hospital of Stomatology, Beijing, China.,National Center of Stomatology and National Clinical Research Center for Oral Diseases and National Engineering Laboratory for Digital and Material Technology of Stomatology, Beijing, China
| | - Jian-Guo Zhang
- Department of Oral and Maxillofacial Surgery, Peking University School and Hospital of Stomatology, Beijing, China.,National Center of Stomatology and National Clinical Research Center for Oral Diseases and National Engineering Laboratory for Digital and Material Technology of Stomatology, Beijing, China
| | - Lei Zheng
- Department of Oral and Maxillofacial Surgery, Peking University School and Hospital of Stomatology, Beijing, China.,National Center of Stomatology and National Clinical Research Center for Oral Diseases and National Engineering Laboratory for Digital and Material Technology of Stomatology, Beijing, China
| |
Collapse
|
4
|
Munnangi A, Kadapathri A, Pillai V, Bhat S, Rajeswarie RT, Shetty V, Subramanium N, Kolur T, Bhushan R V. Isolated Infratemporal Fossa Desmoid Fibromatosis: A Rare Case Report and Review of Literature. Indian J Otolaryngol Head Neck Surg 2022; 74:2609-2613. [PMID: 36452559 PMCID: PMC9702405 DOI: 10.1007/s12070-020-02294-x] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/19/2020] [Accepted: 11/24/2020] [Indexed: 10/22/2022] Open
Abstract
Desmoid fibromatosis (DF) arising from musculoaponeurotic structures rarely affects the head and neck region with the abdomen being the most common site of origin. These are benign tumors with locally infiltrative nature usually presenting as painless swellings that are rapidly growing. The infratemporal fossa DF is an extremely rare location with few clinical reports. This article discusses the management of a 2-year-old child with DF of the infratemporal fossa (ITF) along with literature review.
Collapse
Affiliation(s)
- Ashwini Munnangi
- Head and Neck Oncology, Mazumdar Shaw cancer center, Bangalore, India
| | | | - Vijay Pillai
- Head and Neck Oncology, Mazumdar Shaw cancer center, Bangalore, India
| | - Sunil Bhat
- Pediatric Hematology/Oncology, Mazumdar Shaw cancer center, Bangalore, India
| | | | - Vivek Shetty
- Head and Neck Oncology, Mazumdar Shaw cancer center, Bangalore, India
| | | | - Trupti Kolur
- Head and Neck Oncology, Mazumdar Shaw cancer center, Bangalore, India
| | - Vidya Bhushan R
- Head and Neck Oncology, Mazumdar Shaw cancer center, Bangalore, India
| |
Collapse
|
5
|
Dimachkieh AL, Chelius DC. Complex Head and Neck Resection, Reconstruction, and Rehabilitation in Children. Otolaryngol Clin North Am 2022. [DOI: 10.1016/j.otc.2022.07.018] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/05/2022]
|
6
|
Abstract
Desmoid-type fibromatosis is a rare tumor, particularly in the orbit, with fewer than 10 cases of primary orbital desmoid-type fibromatosis reported in the literature. The authors present a case of an infant who presented with rapid onset of OD proptosis, disc edema, and hyperopic shift who was found to have a retrobulbar desmoid-type fibromatosis. After initial biopsy, due to risk of vision loss with complete excision, the tumor was treated with sorafenib, a tyrosine kinase inhibitor. During the course of treatment with sorafenib, the tumor stabilized and then regressed in size. To the authors' knowledge, this is the first reported case of orbital desmoid-type fibromatosis to be treated with sorafenib.
Collapse
Affiliation(s)
- Elaine M Downie
- Oculoplastic, Facial Cosmetic, and Orbital Surgery, Department of Ophthalmology and Visual Sciences
| | - Christina E Amend
- Division of Pediatric Hematology, Medical Oncology and Palliative Care
| | - Alexander Miranda
- Pediatric Ophthalmology, Department of Ophthalmology and Visual Sciences, University of Wisconsin-Madison, Madison, Wisconsin, U.S.A
| | - Cat N Burkat
- Oculoplastic, Facial Cosmetic, and Orbital Surgery, Department of Ophthalmology and Visual Sciences
| |
Collapse
|
7
|
Sparber-Sauer M, Orbach D, Navid F, Hettmer S, Skapek S, Corradini N, Casanova M, Weiss A, Schwab M, Ferrari A. Rationale for the use of tyrosine kinase inhibitors in the treatment of paediatric desmoid-type fibromatosis. Br J Cancer 2021; 124:1637-46. [PMID: 33723397 DOI: 10.1038/s41416-021-01320-1] [Citation(s) in RCA: 10] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/01/2020] [Revised: 01/27/2021] [Accepted: 02/11/2021] [Indexed: 02/07/2023] Open
Abstract
In children with desmoid-type fibromatosis (DTF) in whom disease progression occurs after an initial watch-and-wait strategy, prolonged low-dose chemotherapy using vinblastine and methotrexate (VBL-MTX) is currently the standard of care. These conventional drugs have been prospectively evaluated but their efficacy and safety profiles are limited, and alternative therapeutic options are therefore essential. Based on the results of clinical trials, the use of tyrosine kinase inhibitors (TKIs) in the treatment of DTF is currently considered only in adult patients. TKIs such as imatinib show superior therapeutic efficacy to VBL-MTX and tolerable short-term side effects for the treatment of adult DFT, supporting the concept of the use of TKIs for the treatment of paediatric DFT. Moreover, new-generation TKIs, such as pazopanib and sorafenib, have shown improved therapeutic efficacy compared to imatinib in adult non-comparative studies. A tolerable safety profile of TKI therapy in children with disease entities other than DTF, such as leukaemia, has been reported. However, the efficacy and, in particular, the long-term safety of TKIs, including childhood-specific aspects such as growth and fertility, for the treatment of children with DTF should be investigated prospectively, as DFT therapy requires long-term drug exposure.
Collapse
|
8
|
Zhao CX, Dombrowski ND, Perez-Atayde AR, Robson CD, Afshar S, Janeway KA, Rahbar R. Desmoid tumors of the head and neck in the pediatric population: Has anything changed? Int J Pediatr Otorhinolaryngol 2021; 140:110511. [PMID: 33271436 DOI: 10.1016/j.ijporl.2020.110511] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 09/18/2020] [Revised: 11/15/2020] [Accepted: 11/16/2020] [Indexed: 12/16/2022]
Abstract
INTRODUCTION Pediatric head and neck desmoid tumors are rare neoplasms that can cause significant morbidity due to infiltration of vital anatomic structures. The goal of this study is to review presentation, evaluation, and management of these tumors. METHODS Retrospective study of children with head and neck desmoid tumors treated from 1999 to 2018 and literature review. RESULTS 11 patients (5 boys, 6 girls) were included. Presentation included firm neck mass (n = 8), trismus (n = 2) and tongue lesion (n = 1). All patients had preoperative imaging with CT (n = 2), MRI (n = 1) or both (n = 8). Five patients underwent needle biopsy, five had open biopsy and one was diagnosed on pathology from primary excision. Seven patients were treated by primary surgical resection, with positive surgical margins in six cases due to proximity to vital neurovascular structures. None needed chemotherapy, had disease recurrence or progression. Three patients with unresectable disease were treated with chemotherapy. One patient was monitored with imaging without any treatment and did not have disease progression. Follow-up ranged from 6 months to 6 years (median 21 months). Ten patients (7 surgical, 2 chemotherapy, 1 observation) were either disease-free or had stable disease at last follow-up. CONCLUSION Pediatric head and neck desmoid tumors, though rare and histologically benign, are locally infiltrative and aggressive. When feasible, surgical treatment results in good disease control despite positive margins. A balance between achieving negative margins and minimizing functional deficits should be considered. Chemotherapy can be successfully utilized in patients where surgery entails a high risk of morbidity and mortality.
Collapse
Affiliation(s)
- Cher X Zhao
- Department of Otolaryngology & Communication Enhancement, Boston Children's Hospital, Boston, MA, United States
| | - Natasha D Dombrowski
- Department of Otolaryngology & Communication Enhancement, Boston Children's Hospital, Boston, MA, United States
| | - Antonio R Perez-Atayde
- Department of Pathology, Boston Children's Hospital, Boston, MA, United States; Department of Pathology, Harvard Medical School, Boston, MA, United States
| | - Caroline D Robson
- Department of Radiology, Boston Children's Hospital, MA, United States; Department of Radiology, Harvard Medical School, Boston, MA, United States
| | - Salim Afshar
- Department of Plastic & Oral Surgery, Boston Children's Hospital, Boston, MA, United States; Department of Oral and Maxillofacial Surgery, Harvard Medical School, Boston, MA, United States
| | - Katherine A Janeway
- Pediatric Hematology/Oncology, Dana-Farber Cancer Institute, Boston, MA, United States; Department of Pediatrics, Harvard Medical School, Boston, MA, United States
| | - Reza Rahbar
- Department of Otolaryngology & Communication Enhancement, Boston Children's Hospital, Boston, MA, United States; Department of Otolaryngology, Harvard Medical School, Boston, MA, United States.
| |
Collapse
|
9
|
Duhil de Bénazé G, Vigan M, Corradini N, Minard-Colin V, Marie-Cardine A, Verite C, Defachelles AS, Thebaud E, Castex MP, Sirvent N, Bodet D, Mansuy L, Rome A, Petit A, Plantaz D, Jourdain A, Mary P, Carton M, Orbach D. Functional analysis of young patients with desmoid-type fibromatosis: Initial surveillance does not jeopardize long term quality of life. Eur J Surg Oncol 2020; 46:1294-1300. [PMID: 32173177 DOI: 10.1016/j.ejso.2020.02.028] [Citation(s) in RCA: 9] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/08/2019] [Revised: 02/11/2020] [Accepted: 02/20/2020] [Indexed: 12/19/2022] Open
Abstract
BACKGROUND With recent conservative strategies, prognosis of patients with desmoid-type fibromatosis (DTF) is about function preservation. We analyzed the long-term quality of life (QoL) of pediatric patients with DTF. METHODS All French young patients (<21years) treated between 2005 and 2016 for a DTF in the EpSSG NRSTS-05 study were analyzed. A first wait-and-see strategy was recommended. Patients' QoL was analyzed with the internationally validated Child Health Questionnaire (CHQ). We focused on the relevant subscales scores: physical functioning (PF), role social limitations physical (RP), bodily pain (BP), general health perception (GH) and physical (PhS) and psychosocial (PsS) summary measures. RESULTS Among the 81 patients, 52 families answered the CHQ (median delay since diagnosis = 6.2years; min2.2-max13.3 years). Median age at diagnosis was 11.5 years. Primary site: limbs (52%), head/neck (27%), or trunk (21%). Five year-Progression Free Survival was 39.1% (95%CI: 27.7-50.5%). As initial management for these 52 patients, 30 patients were first observed (57%), 13 had surgery (25%) and 9 received chemotherapy (18%). Total burden of therapy was exclusive surgery (9pts/18%), exclusive chemotherapy (18pts/35%), surgery + chemotherapy (13pts/25%), chemotherapy + radiotherapy (1 pt), surgery + chemotherapy + radiotherapy (1 pt), wait and see (10 pt). Regarding the parent forms, patients have significant lower PF (86.0vs.96.1; p = 0.03), RP (82.0vs.93.6; p = 0.04), GH (60vs.73; p < 0.005) and PhS (46.2 vs.53; p = 0.02) scores compared to healthy population. Comparison of QoL subscales scores according to initial strategy (wait-and-see vs.surgery/chemotherapy) did not reveal any difference (PF = 87.3vs.84.9; p = 0.80/RP = 83.4vs.78.7; p = 0.72/BP = 78.9vs.78.2; p = 0.95/GH = 59.7vs60; p = 0.97). Similar results were found using the children or adult forms. CONCLUSIONS Initial wait-and-see strategy does not affect long term functional impairment.
Collapse
Affiliation(s)
- G Duhil de Bénazé
- University Hospital of Nice- Archet 2, Department of Pediatric Hematology-Oncology, Nice, France; Institut Curie, SIREDO Oncology Center Care- Innovation and Research for Children and AYA with Cancer- PSL Research University, Paris, France.
| | - M Vigan
- Institut Curie- PSL Research University, Biometry Unit, Paris, France
| | - N Corradini
- IHOPe, Centre Régional de Lutte Contre le Cancer- Centre Léon Bérard, Lyon, France
| | - V Minard-Colin
- Gustave Roussy Cancer Campus, Department of Children and Adolescents Oncology, Villejuif, France
| | - A Marie-Cardine
- Rouen University Hospital, Department of Pediatric Hematology-Oncology, Rouen, France
| | - C Verite
- Bordeaux University Hospital, Pediatric Hematology Department, Bordeaux, France
| | - A S Defachelles
- Centre Oscar Lambret, Service D'Oncologie Pédiatrique, Lille, France
| | - E Thebaud
- University Hospital Nantes, Pediatric Oncology Department, Nantes, France
| | - M P Castex
- Children's Hospital of Toulouse- CHU Toulouse, Pediatric Hemato-oncology Department, Toulouse, France
| | - N Sirvent
- University Hospital of Montpellier, Department of Pediatric Onco-Hematology, Montpellier, France
| | - D Bodet
- Caen University Hospital, Department of Pediatric Hematology and Oncology, Caen, France
| | - L Mansuy
- Children's University Hospital, Department of Pediatric Hematology and Oncology, Nancy, France
| | - A Rome
- Centre Hospitalier Universitaire, Department of Pediatric Oncology, Marseille, France
| | - A Petit
- Assistance Publique-Hôpitaux de Paris AP-HP- GH HUEP- Armand Trousseau Hospital, Department of Pediatric Hematology and Oncology, Paris, France
| | - D Plantaz
- University Hospital Centre of Grenoble, Department of Pediatric Hematology-Oncology, Grenoble, France
| | - A Jourdain
- CHU Tours, Department of Pediatric Oncology and Hematology, Tours, France
| | - P Mary
- Pediatric Orthopedics Department, Armand Trousseau Hospital, Paris, France
| | - M Carton
- Institut Curie- PSL Research University, Biometry Unit, Paris, France
| | - D Orbach
- Institut Curie, SIREDO Oncology Center Care- Innovation and Research for Children and AYA with Cancer- PSL Research University, Paris, France
| |
Collapse
|